ClinicalTrials.gg
CompletedNCT03461575Updated May 8, 2020

Efficacy and Safety of HU007 Eye Drops in Patients With Dry Eye Syndrome

A Phase 3 interventional study of HU007 and Restasis in Dry Eye Syndrome, sponsored by Huons Co., Ltd.. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2020-05-08.

Sponsored by Huons Co., Ltd. (part of Huons Global) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
209
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 58 studies in Dry Eye Syndromes with a site in Korea, Republic of — 5 open to participants now, 6 under way, 1 of them phase 3. Dry Eye Syndromes · Korea, Republic of.

Enrollment
10th of 52
209 · median 99
Started
2018
with 2 others
Phase 3
16 of 58
1 open now
Registered
21st of 58
by date
Lead sponsor
6 of 58
Huons Co., Ltd.

Among the 58 studies in Dry Eye Syndromes with a site in Korea, Republic of, this one is the 10th largest by enrollment of the 52 interventional ones that give a count, is one of 3 that started in 2018, is one of 16 in phase 3, and was the 21st registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

5 of the 58 studies in Dry Eye Syndromes with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Dry Eye Syndromes with a site in Korea, Republic of, or all of them as a file.
02

Study summary

A multicenter, Randomized, Double blind, Restasis®-controlled Non-inferiority, Moisview® Eye Drops-controlled Superiority, Phase III Study to Evaluate the Efficacy and Safety of HU007 Eye Drops in Patients with Dry Eye Syndrome

03

Conditions studied

  • Dry Eye Syndrome

Browse trials for

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age over 19
  • Corneal staining score(Oxford grading) ≥ 2 or Schirmer test ≤ 10mm/5min (If Schirmer test = 0mm/5min, Nasal stimulation schirmer test ≥ 3mm/5min)
  • Volunteer who went through menopause more than 1 years ago before screening or has surgical menopause or who has negative result of pregnancy test or use effective

Exclusion criteria

Exclusion Criteria:

  • The patients with systemic or ocular disorders affected the test result
  • Current or recent patients used dry eye syndrome medications (topical or systemic) that may affect the status
  • Being treated with systemic
  • Wearing contact lenses within 72 hr of screening visit
  • Pregnancy or Breastfeeding
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Double (Participant, Investigator)
Enrollment
209 participants (actual)

Study arms

  • Experimental
    HU007

    Cyclosporine 0.02%, trehalose 3% 1 drop b.i.d at 12hr interval for 12 weeks

    Drug: HU007

  • Active comparator
    Restasis

    Cyclosporine 0.05% 1 drop b.i.d at 12hr interval for 12 weeks

    Drug: Restasis

  • Active comparator
    Moisview

    trehalose 3% 1 drop b.i.d at 12hr interval for 12 weeks

    Drug: Moisview

Interventions

  • DrugHU007

    cyclosporine 0.02%, trehalose 3%

  • cyclosporine 0.05%

  • DrugMoisview

    trehalose 3%

06

What researchers measure

Primary outcomes

  1. change from Baseline in Corneal staining(Oxford grading) score

    Time frame: Week 12

Secondary outcomes

  1. change from Baseline in Corneal staining(Oxford grading) score

    Time frame: Week 4,8

  2. change from Baseline of Conjunctival staining(Oxford grading) score

    Time frame: Week 4,8,12

  3. change from Baseline of Strip meniscometry assessment

    Time frame: Week 4,8,12

  4. change from Baseline of Tear film break-up time

    Time frame: Week 4,8,12

  5. change from Baseline of Standard patient evaluation of eye dryness questionnaire

    Time frame: Week 4,8,12

  6. arrival time of 100% clearence in Corneal staining test

    Time frame: Week 0-12

  7. The number of total rescue drug usage

    Time frame: Week 0-12

07

Study locations

1 site
  • Seoul ST.Mary's Hospital
    Seoul, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2018 to primary completion in Jul 2018, 5 months.

Of 81 industry-sponsored phase 3 interventional studies under Dry Eye Syndromes, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 15. This study's 5 months is below that.

Counting every sponsor, half of 96 studies reached it within 10 months; a quarter within 7 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2018
First posted
Mar 12, 2018
StartActual
Jan 22, 2018
Primary completionActual
Jul 12, 2018
CompletionActual
Jul 12, 2018
Last update
May 8, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03461575
Lead sponsor
Huons Co., Ltd.
Responsible party
Sponsor
First posted
Mar 12, 2018
Start date
Jan 22, 2018
Primary completion
Jul 12, 2018
Completion
Jul 12, 2018
Last update
May 8, 2020

Study contacts

Namsick Kim
study director · Huons Co., Ltd.
Choun-Ki Joo
principal investigator · Seoul St. Mary's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HU007

Start the discussion